Market-Moving Exclusives

EXCLUSIVE: Toppoint Signs MoU With Peru's Chancay Municipality To Overhaul Waste Management

EXCLUSIVE: Intelligent Bio Solutions Expands US Forensic Market Presence, Seeks FDA Clearance For Fingerprint Drug Testing

EXCLUSIVE: Adial Pharmaceuticals Lead Candidate For Alcohol Use Disorder Advances Toward Phase 3 Trial

EXCLUSIVE: Intelligent Bio Solutions Expands US Forensic Market Presence, Seeks FDA Clearance For Fingerprint Drug Testing

EXCLUSIVE: Adial Pharmaceuticals Lead Candidate For Alcohol Use Disorder Advances Toward Phase 3 Trial

EXCLUSIVE: Ideal Power Taps Kaimei Electronic To Distribute Products Across Asia

EXCLUSIVE: Telomir Pharmaceuticals Lead Drug Shows Promising Signs In Animal Study For Rare Premature Aging Disorder

EXCLUSIVE: Ideal Power Taps Kaimei Electronic To Distribute Products Across Asia

EXCLUSIVE: Telomir Pharmaceuticals Lead Drug Shows Promising Signs In Animal Study For Rare Premature Aging Disorder

EXCLUSIVE: Beeline Launches Stablecoin-Backed Home Equity Product, Targets Profitability By Late 2025

EXCLUSIVE: Vivakor Bets On Permian Boom With 10 Crude Hubs

Market-Moving Exclusives Recent News

EXCLUSIVE: Vivakor Announces Special Stock Dividend

Vivakor (VIVK) announced a special dividend for shareholders, based on their holdings in Adapti (BRZLD). Value of dividend is approx. 0.0079 shares per VIVK share.

EXCLUSIVE: SKYX Secures Deal To Wire 5,700 Smart Homes In Miami's Smart Home Project

SKYX (NASDAQ: SKYX) partners with SG Holdings to supply smart home tech for 63-acre mixed-use smart city in Miami, transforming urban living with advanced technology.

EXCLUSIVE: Telomir Pharma To Raise $3 Million Via Equity Financing To Fund Its Rare Disease IND

Telomir Pharma (NASDAQ: TELO) secured $3M in equity financing from Bayshore Trust, its largest shareholder, at $3 per share (18% premium). It also has a $5M credit line. It has 2 innovative drug candidates targeting aging and infections, with promising preclinical results.

EXCLUSIVE: GT Biopharma Advances Relapsed Blood Cancer Therapy Trial To Cohort 2 After Promising Early Safety Results

GTBP announces completion of dosing in Cohort 1 and start of dosing in Cohort 2 of Phase 1 trial for GTB-3650, showing potential for NK cell expansion and increased immunologic activity. Detailed results to be released in 2025. GTBP stock up 0.90%.

EXCLUSIVE: Channel Therapeutics Touts Positive Efficacy Results For Eye Treatment Potential In Multiple Preclinical In Vivo Models

Channel Therapeutics reports CT2000 reduced eye pain in preclinical trials, with plans to enter human testing for acute and chronic indications.

EXCLUSIVE: Intelligent Bio Solutions Q3 Gross Profit Jumps By 91%

Intelligent Bio Solutions reported a Q3 loss of 44 cents per share with a 20% revenue rise from Q2 and 91% year-over-year gross profit growth.

EXCLUSIVE: Alzamend Neuro Initiates First Phase 2 Trial Of Lead Program In Healthy Human Participants

Alzamend Neuro starts Phase 2 trial of AL001 with novel coil tech to test improved lithium delivery in the brain for multiple mental health conditions.

EXCLUSIVE: FDA Clears Lantern Pharma's Planned Phase 1b/2 Trial of LP-184 In Treatment-Resistant Lung Cancer Patients

Lantern Pharma receives FDA clearance to begin Phase 1b/2 trial of LP-184 in advanced NSCLC patients with key mutations and low PD-L1 expression.

EXCLUSIVE: DeFi Development Makes Record Solana Purchase, Surpasses $100 Million In Treasury Holdings

DeFi Dev Corp purchased 172,670 SOL at $136.81 each, totaling $23.6M. They now hold $102.7M worth of SOL, with plans for long-term staking.

EXCLUSIVE: Inuvo Clocks 57% Topline Growth, Margin Shrinks Due To Product Mix

Inuvo announced Q1 results with $26.7M revenue (highest in history), 41% gross profit increase, $0.01 loss per share, and $22K EBITDA loss.

EXCLUSIVE: Adial Pharmaceuticals Secures FDA End of Phase 2 Meeting Request To Discuss Upcoming Clinical Development Plan For Lead Program

FDA schedules End of Phase 2 meeting with Adial to discuss Phase 3 plans for AD04, its genetically targeted drug for Alcohol Use Disorder.

EXCLUSIVE: Mira Pharmaceuticals Board Approves SKNY Pharma Acquisition, Establishing Combined Enterprise Value Over $60 Million

Mira Pharmaceuticals to acquire SKNY in a stock-based deal valuing both firms near $30 million each, backed by third-party pipeline valuation reports.

EXCLUSIVE: Aduro's Deal With Cleanfarms Targets Farm Plastic Recycling Revolution And Scalable Sustainability

Aduro Clean Technologies Inc. (Nasdaq: ADUR) signed an MOU with Cleanfarms to explore using Aduro's HCT for chemically recycling difficult-to-process plastic waste in agriculture.